MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops, and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.
| Website | http://www.mgipharma.com |
| Revenue | $64 million |
| Employees | View employees |
| Address | 6300 West Old Shakopee Ste. 110, Minneapolis, Minnesota 55438, US |
| Phone | (612) 935-7335 |
| Industry | Healthcare, Pharmaceuticals, Drug Manufacturing & Research, Biotechnology |
| Competitors | Amgen, Bristol Myers Squibb, AstraZeneca, Gilead Sciences, AbbVie, Vertex Pharmaceuticals, Sanofi, Regeneron, Jazz Pharmaceuticals, Receptos, a wholly-owned subsidiary of Celgene +46 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325412 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Mgi Pharma , Inc. employee's phone or email?
Mgi Pharma , Inc. Questions
The Mgi Pharma , Inc. annual revenue was $64 million in 2026.
Mgi Pharma , Inc. is based in Minneapolis, Minnesota.
The NAICS codes for Mgi Pharma , Inc. are [325412, 325, 3254, 32541, 32].
The SIC codes for Mgi Pharma , Inc. are [28, 283].
